


TPPU

Cat. No.:	HY-101294		
CAS No.:	1222780-33-7		
Molecular Formula:	C ₁₆ H ₂₀ F ₃ N ₃ O ₃		
Molecular Weight:	359.34		
Target:	Epoxide Hydrolase		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 83.33 mg/mL (231.90 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.7829 mL	13.9144 mL	27.8288 mL
	5 mM	0.5566 mL	2.7829 mL	5.5658 mL
	10 mM	0.2783 mL	1.3914 mL	2.7829 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.08 mg/mL (5.79 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (5.79 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.79 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

TPPU is a soluble epoxide hydrolase (sEH) inhibitor with IC₅₀ values of 37 and 3.7 nM for monkey and human sEH, respectively.

IC₅₀ & Target

IC₅₀: 37 nM (Monkey sEH), 3.7 nM (Human sEH)^[1]

In Vitro

Soluble epoxide hydrolase inhibitors (sEHIs) possess anti-inflammatory, antiatherosclerotic, antihypertensive and analgesic properties^[1]. In the Caco-2 cells permeability assay, TPPU rapidly passes the cell monolayer, suggesting it will have a good

intestinal permeability^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

TPPU is suitable for investigating soluble epoxide hydrolase biology and the role of epoxide-containing lipids in modulating inflammatory diseases. TPPU displays high plasma concentrations when dosed orally at 0.3 mg/kg and drug-like properties. The C_{max} increases with dose from 0.3 to 3 mg/kg for TPPU^[1]. Following administration in drinking water to rats (0.2, 1, and 5 mg TPPU/L with 0.2% PEG400), TPPU's blood concentration increases dose dependently within the treatment period to reach an almost steady state after 8 days^[2]. The sEH inhibitor, TPPU, shows antidepressant effects in animal models of depression. Expression of sEH protein is increased in the brain of chronically stressed mice and depressed patients.

Prophylactic sEH inhibition or sEH-KO results in resilience to repeated social defeat stress, associated with increased BDNF-TrkB signaling in prefrontal cortex and hippocampus of KO mice^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[2]

Cell monolayers that exceeds a resistance of $300 \Omega \text{ cm}^{-2}$ are incubated with either 1 μM or 10 μM of TPPU solution in DMSO on the apical side. Medium samples on the apical and basolateral side are collected and frozen immediately after 1, 3 and 6 hours. The apparent permeability coefficient is calculated for $t=1 \text{ h}$ ^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^{[1][2]}

Rats: Water is provided ad libitum containing 0.2% PEG400 with and without TPPU at a concentration of 0.2 mg/L, 1 mg/L and 5 mg/L during the treatment period (8 days). Before (0 h) and after 2 h, 4 h, 8 h, 1 d, 2 d, 4 d and 8 d, 10 μL blood are sampled from the tail vein. The blood is directly mixed with 50 μL deionized water²⁸ and frozen until analysis. On day 8, the animals are sacrificed by cardiac puncture after anesthesia. Plasma and whole blood are sampled^[2].

Monkeys: TPPU is prepared in 0.3, 1 and 3 mg/kg doses and is administered to four animals with 48 h dosing intervals based on the $t_{1/2}$ of the compound obtained from the first cassette dosing. Blood is collected from animals at time points 0, 0.25, 0.5, 1, 2, 3, 4, 8, 24 and 48 h after each dosing for analysis^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Hypertension. 2021 Nov;78(5):1527-1540.
- J Transl Med. 2024 Jan 16;22(1):61.
- Biochim Biophys Acta Mol Basis Dis. 2023 Jan 18;1869(4):166643.
- Biomedicines. 2021, 9(7), 828.
- Mol Cell Endocrinol. 2020 Dec 30;111149.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Ulu A, et al. Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys. Br J Pharmacol. 2012 Mar;165(5):1401-12.

[2]. Ostermann AI, et al. Oral treatment of rodents with soluble epoxide hydrolase inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU): Resulting drug levels and modulation of oxylipin pattern. Prostaglandins Other Lipid Mediat. 2015 Sep;121(Pt A):131-7.

[3]. Ren Q, et al. Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress. Proceedings of the National Academy of Sciences of the United States of America (2016), 113(13), E1944-E1952.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA